Phenotypic modulation of smooth muscle cells and matrix metalloproteinases as targets for atherosclerotic plaque stabilization

Abstract

Atherosclerosis and its complications, erosion and rupture of the plaque fibrous cap, lead to myocardial infarction and stroke, the main causes of mortality worldwide. In this setting, arterial smooth muscle cells (SMC) of the innermost media undergo phenotypic changes, a switch towards a secretory phenotype engaged in matrix proteins production. In its nature, this is a protective action that forms of a new arterial layer, the fibrous cap covering the plaque thrombogenic lipid core. The risk of plaque rupture is inversely correlated with the presence of secretory state SMC and collagen fibrils within the fibrous cap. Thus, fibrous cap remodeling appears to be the main determinant of plaque vulnerability. Herein, we focus on the potential role of (i) the transcription factors TCF21 and KLF-4 in SMC phenotypic modulation, (ii) the matrix protein secretion of SMC, and (iii) the activity of proteinases (MMP, ADAM, ADAMTS, furin, and the MMP inducer CD147) in this critical process. We argue that focusing on these basic pathways could contribute to the knowledge of fibrous cap stability that might be translated into clinical medicine.

Colchicine and therapy of cardiovascular disease: Not merely a theory

“…Based on the results published for the first time during the 1970's and early 1980's by one of us (GNC), we had proposed that antitubulins, particularly colchicine, could be effective in the therapy of CVD (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13).…”

“…Of note, arterial smooth muscle cells (SMC) of the innermost media undergo phenotypic modulation towards a secretory state involved in (pro)collagen and other matrix proteins production. The risk of plaque rupture is inversely correlated with the presence of secretory phenotype SMC and collagen fibrils within the plaque fbrous cap (8)(9)(10).…”